Scientists have developed a noninvasive device that may not only detect melanoma cells traveling through the bloodstream, but also kill them. The device, which the investigators call Cytophone, accurately detected cancer cells in 27 […]
ELAA Technology: Early Lung Cancer Detection
ELAA Technology, an Istanbul-based company, has developed a software application which is used in conjunction with a bronchoscopy unit. By providing a patient’s Computerized Tomography (CT) images and bronchoscopy camera feed, it […]
Paige: Medical AI at an Unprecedented Scale
Paige, a New York-based company, is working to revolutionize the diagnosis and treatment of cancer by providing pathologists, clinicians and researchers with insights drawn from decades of data diagnosed by world experts […]
Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer
Some types of cancer cells are surrounded by a dense layer of connective tissue that acts as a barrier to cancer-killing immune cells. That poses a problem for immunotherapies, treatments that depend on interactions […]
T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast Cancer
The Food and Drug Administration (FDA) has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla) to treat some women with HER2-positive breast cancer. Ado-trastuzumab, also called T-DM1, was initially approved by FDA more […]
Avelas Biosciences: Detecting Cancer in Real-Time
Avelas Biosciences, a California-based clinical-stage oncology company, is developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 works to improve surgery by detecting cancer in real-time and has […]
MiraDX: Unique MicroRNA-based Biomarkers
MiraDx, a Los Angeles-based company, is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant. They are developing answers by applying their novel […]
Cellanyx: Harnessing the Power of Live Primary Cell Phenomics
Cellanyx, a Massachusetts-based diagnostic company, has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. Their unique approach provides quantitative and actionable information […]